The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study
Open accessAbstract
AIMS: Estimate the prevalence of cannabis dependence and its contribution to the global burden of disease. METHODS: Systematic reviews of epidemiological data on cannabis dependence (1990-2008) were conducted in line with PRISMA and meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Culling and data extraction followed protocols, with cross-checking and consistency checks. DisMod-MR, the latest version of generic disease modelling system, redesigned as a Bayesian meta-regression tool, imputed prevalence by age, year and sex for 187 countries and 21 regions. The disability weight associated with cannabis dependence was estimated through population surveys and multiplied by prevalence data to calculate the years of life lived with disability (YLDs) and disability-adjusted life years (DALYs). YLDs and DALYs attributed to regular cannabis use as a risk factor for schizophrenia were also estimated. RESULTS: There were an estimated 13.1 million cannabis dependent people globally in 2010 (point prevalence0.19% (95% uncertainty: 0.17-0.21%)). Prevalence peaked between 20-24 yrs, was higher in males (0.23% (0.2-0.27%)) than females (0.14% (0.12-0.16%)) and in high income regions. Cannabis dependence accounted for 2 million DALYs globally (0.08%; 0.05-0.12%) in 2010; a 22% increase in crude DALYs since 1990 largely due to population growth. Countries with statistically higher age-standardised DALY rates included the United States, Canada, Australia, New Zealand and Western European countries such as the United Kingdom; those with lower DALY rates were from Sub-Saharan Africa-West and Latin America. Regular cannabis use as a risk factor for schizophrenia accounted for an estimated 7,000 DALYs globally. CONCLUSION: Cannabis dependence is a disorder primarily experienced by young adults, especially in higher income countries. It has not been shown to increase mortality as opioid and other forms of illicit drug dependence do. Our estimates suggest that cannabis use as a risk factor for schizophrenia is not a major contributor to population-level disease burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders
Knapp, W. P., Soares, B., Farrell, M., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003023.pub2 · Cited by 178
RetractedPsychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings
Denis, C., Lavie, E., Fatseas, M., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub2 · Cited by 128
RetractedPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citationLim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Self-citationMurray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Self-citationDiagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Self-citation
Cited by
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Self-citationWhiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175
Self-citationErskine, H. E., Moffitt, T. E., Copeland, W. E., Costello, E. J., Ferrari, A. J., Patton, G., Degenhardt, L., Vos, T., Whiteford, H. A., & Scott, J. G. (2015) · Psychological Medicine · doi:10.1017/s0033291714002888 · Cited by 688
Self-citationThe increasing global health priority of substance use in young people
Degenhardt, L., Stockings, E., Patton, G., Hall, W. D., & Lynskey, M. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00508-8 · Cited by 601
Self-citationLower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 433
Self-citationGlobal statistics on addictive behaviours: 2014 status report
Gowing, L. R., Ali, R. L., Allsop, S., Marsden, J., Turf, E. E., West, R., & Witton, J. (2015) · Addiction · doi:10.1111/add.12899 · Cited by 410
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis
Davis, J., Eyre, H., Jacka, F. N., Dodd, S., Dean, O., McEwen, S., Debnath, M., McGrath, J., Maes, M., Amminger, P., et al. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.017 · Cited by 355
Self-citationBlanco, C., Hasin, D. S., Wall, M. M., Flórez-Salamanca, L., Hoertel, N., Wang, S., Kerridge, B. T., & Olfson, M. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3229 · Cited by 336
Kedzior, K. K., & Laeber, L. T. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-136 · Cited by 309
Russell, C., Rueda, S., Room, R., Tyndall, M., & Fischer, B. (2018) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.11.008 · Cited by 298
Hunt, G. E., Malhi, G. S., Lai, H. M. X., & Cleary, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.141 · Cited by 289
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure
Levine, A., Clemenza, K., Rynn, M., & Lieberman, J. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.12.014 · Cited by 239
Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., Brink, W. V. D., et al. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103381 · Cited by 236
“Furthermore, it is estimated that only about 2% or less of PWUC experience a severe cannabis-induced mental health problem (e.g., psychosis, schizophrenia) ( Curran et al., 2016 ; Hall & Degenhardt, 2008 , Hall & Degenhardt, 2010 ).”
BackgroundThe cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
“2%.(4) There is a significant positive correlation between the region’s economic situation and the prevalence of cannabis dependence.”
InfluentialA literature review and meta-analyses of cannabis use and suicidality
Borges, G., Bagge, C. L., & Orozco, R. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.007 · Cited by 214
Effects of increasing cannabis potency on adolescent health
Wilson, J., Freeman, T. P., & Mackie, C. J. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30342-0 · Cited by 113
Risso, C., Boniface, S., Subbaraman, M. S., & Englund, A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120919970 · Cited by 87
“8 million cases of cannabis-use disorder where estimated (Degenhardt et al., 2013; Peacock et al., 2018).”
BackgroundInfluentialPower, E., Sabherwal, S., Healy, C., O’ Neill, A., Cotter, D., & Cannon, M. (2021) · Psychological Medicine · doi:10.1017/s0033291720005036 · Cited by 34
Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal.
Kevin, R. C., Allsop, D. J., Lintzeris, N., Dunlop, A. J., Booth, J., & McGregor, I. S. (2017) · Forensic Toxicology · doi:10.1007/s11419-016-0330-0 · Cited by 24
Cost-Effectiveness of School-Based Prevention of Cannabis Use
Deogan, C., Zarabi, N., Stenström, N., Högberg, P., Skärstrand, E., Manrique-Garcia, E., Neovius, K., & Månsdotter, A. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-015-0175-4 · Cited by 20
Nnam, M. U., Onya, V. O., Obi, C. F., Ogbonnaya, C. E., & Arua, M. C. (2021) · Scientific African · doi:10.1016/j.sciaf.2021.e00799 · Cited by 11
Metadata
- Authors
- Degenhardt, L., Ferrari, A. J., Calabria, B., Hall, W. D., Norman, R. E., McGrath, J., Flaxman, A. D., Engell, R. E., Freedman, G. D., Whiteford, H. A., & Vos, T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-24
- Volume
- 8
- Issue
- 10
- Pages
- e76635
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1757260719
- Cited by
- 298
- References
- 42
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.